drugset / Trial / NCT06317220
Vedolizumab for the Treatment of Collagenous Gastritis
Phase 2
Active not recruiting
11 enrolled
Massachusetts General Hospital
Dana-Farber Cancer Institute · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are: * Whether vedolizumab can reduce CG symptoms * Whether vedolizumab is safe to take for patients with CG Participants in this study will: * Receive vedolizumab through an IV ("infusion") * Complete a survey at each infusion visit * Have blood collected at each infusion visit * Undergo an endoscopy with biopsy at 2 timepoints
Timeline
- Start
- 2024-12-03
- Primary completion
- 2026-02-17
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vedolizumab | Monoclonal antibody | 300 mg | Intravenous |